Blog

Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 19 • 2 min read

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference, taking…

Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry

Jun 19 • 4 min read

CORAL GABLES, Fla., June 18, 2024 /PRNewswire/ — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical Psychiatry. The article is titled, “Efficacy and Safety of Esmethadone (REL-1017) in Patients…

Psychedelic Retreats Market Set to Cross $1 Trillion By 2027

Jun 14 • 6 min read

The market for psychedelic retreats is on a remarkable trajectory, with projections indicating it will surpass the $1 trillion mark by 2027. This anticipated milestone reflects the rapid expansion and increasing acceptance of psychedelic therapy as an effective treatment for various mental health conditions. The combination of scientific research, regulatory advancements, and shifting societal attitudes…

UC Berkeley’s Groundbreaking Study Exploring Psilocybin’s Effects on Perception

Jun 14 • 6 min read

The UC Berkeley Center for the Science of Psychedelics has embarked on an unprecedented study to explore why psilocybin, a psychoactive compound found in certain mushrooms, alters visual perception in humans. This investigation represents the university’s first human trials involving a Schedule I substance, classified by the federal government as having no accepted medical use….

Lykos Therapeutics Addresses Concerns Over MDMA Treatment for PTSD

Jun 14 • 5 min read

A week after an FDA committee voted against recommending midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD), Lykos Therapeutics is working to clarify the situation and address concerns that have emerged in the broader conversation. This effort comes in the wake of significant public discourse surrounding the potential benefits and risks associated with the psychoactive…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538